American Association for Cancer Research
21598290cd140014-sup-fig4.pdf (303.83 kB)

Supplementary Figure 4 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism

Download (303.83 kB)
journal contribution
posted on 2023-04-03, 20:42 authored by Christopher A. French, Shaila Rahman, Erica M. Walsh, Simone Kühnle, Adlai R. Grayson, Madeleine E. Lemieux, Noam Grunfeld, Brian P. Rubin, Cristina R. Antonescu, Songlin Zhang, Rajkumar Venkatramani, Paola Dal Cin, Peter M. Howley

PDF file - 304KB, Supplementary Fig. S4. Among several ET-interacting proteins, only NSD3 is required for the blockade of differentiation in NMC. (A) Quantitative RT-PCR of NSD3, JMJD6, GLTSCR1, and ATAD5 levels 24 h following transfection of siRNAs. (B) Immunoblots of TC-797 lysates 120h following transfection with siRNAs.



NUT midline carcinoma (NMC) is an aggressive subtype of squamous cell carcinoma that typically harbors BRD4/3–NUT fusion oncoproteins that block differentiation and maintain tumor growth. In 20% of cases, NUT is fused to uncharacterized non-BRD gene(s). We established a new patient-derived NMC cell line (1221) and demonstrated that it harbors a novel NSD3–NUT fusion oncogene. We find that NSD3–NUT is both necessary and sufficient for the blockade of differentiation and maintenance of proliferation in NMC cells. NSD3–NUT binds to BRD4, and BRD bromodomain inhibitors induce differentiation and arrest proliferation of 1221 cells. We find further that NSD3 is required for the blockade of differentiation in BRD4–NUT-expressing NMCs. These findings identify NSD3 as a novel critical oncogenic component and potential therapeutic target in NMC.Significance: The existence of a family of fusion oncogenes in squamous cell carcinoma is unprecedented, and should lead to key insights into aberrant differentiation in NMC and possibly other squamous cell carcinomas. The involvement of the NSD3 methyltransferase as a component of the NUT fusion protein oncogenic complex identifies a new potential therapeutic target. Cancer Discov; 4(8); 928–41. ©2014 AACR.This article is highlighted in the In This Issue feature, p. 855